$NOVO B (+5,32 %) or $LLY (+0,32 %) ?
I think I'll bet on both, you?
Puestos
102$NOVO B (+5,32 %) or $LLY (+0,32 %) ?
I think I'll bet on both, you?
Podcast episode 77 "Buy High. Sell Low."
Subscribe to the podcast to get Novo & AMD back on track.
00:00:00 Novo Nordisk $NVO (+5,14 %)
$LLY (+0,32 %)
00:26:00 BYD $1211 (+2,45 %)
$TSLA (-4,32 %)
00:44:30 Nu Holdings $NU (-11,11 %)
01:07:00 AMD $AMD (-2,29 %)
$NVDA (-3,63 %)
$INTC (-4,07 %)
01:29:00 Election programs SPD & Greens
Spotify
https://open.spotify.com/episode/5PLVDJVROTrUKYtHMWj2Yz?si=5PvCiTPWRPaYPyQ3XcV-Iw
YouTube
https://youtu.be/Z2WkTM1NB6M?si=gXx_9DWNQpwkbDna
Apple Podcast
Today, Novo N has already come close to resistance twice.
Yesterday had $LLY (+0,32 %) delivered similar figures to Novo.
Both shares are moving upwards. Then today more good news from LLY.
My hope is that one will pull the other along and the resistance will therefore not be so strong. After that, things could move quickly.
What do you think?
Have you had any home runs (from +15% price jump) this earnings season?
I haven't yet - hope for $ELF (+5,42 %) and $RIVN (-10,51 %) ...
... but I've also been hoping for $NVO (+5,14 %) , $ARM (-3,76 %)
$AMD (-2,29 %)
$LLY (+0,32 %) in vain so far ...
Forecast for 2025
Elly Lilly reported Q4 EPS of $5.32, $0.02 higher than the analyst estimate of $5.30.
Revenue for the quarter totaled $13.53B, compared to the average estimate of $13.78B.
Forecast:
Eli Lilly expects EPS of $22.50-24.00 in fiscal 2025. Analysts had expected an average of $22.69.
Eli Lilly estimates revenue of $58.00B-$61.00B in fiscal year 2025. Experts had expected an average of $58.91B.
The US pharmaceutical company Eli Lilly expects significant profit growth in 2025 and is focusing on expanding its popular diabetes and weight loss drugs into new markets.
"We are starting 2025 with a strong tailwind," explained CEO David Ricks on Thursday. The manager anticipates an increase in adjusted earnings per share to between 22.50 and 24.00 dollars - analysts had previously expected 22.86 dollars.
Last year, earnings per share more than doubled to 12.99 dollars. "2024 was an extremely successful year for Lilly," said Ricks. The Group invested billions in expanding its production capacities and brought important new growth drivers onto the market.
The pharmaceutical company is flying high thanks to high demand for its diabetes drug Mounjaro and its weight loss injection Zepbound.
Sales rose by almost a third to a good 45 billion dollars in 2024. Sales of Mounjaro skyrocketed to 11.54 billion dollars from 5.16 billion dollars. Zepbound - which only came onto the market at the end of 2023 - earned the Group 4.93 billion dollars.
In the fourth quarter, however, sales of both drugs were below market expectations - a situation that the company had already warned about in January.
Lilly blames this on financial and logistical bottlenecks at wholesalers. However, some investors are also expressing concerns about declining demand for GLP-1 drugs, which include Zepbound and Novo Nordisk's rival product Wegovy.
Both suppliers currently dominate the rapidly growing market for weight loss drugs, which it is estimated could grow to 150 billion dollars by the early 2030s.
🔹 EPS: $4.88 (Est. $4.94) 🔴; UP +102% YoY
🔹 Revenue: $13.53B (Est. $13.66B) 🔴; UP +45% YoY
🔹 Net Income: $4.41B; UP +101% YoY
🔹 Gross Profit Margin: 82.2% (Est. 81.62%) 🟢
FY25 Guidance :
🔹 Revenue: $58.0B - $61.0B (Est. $59.22B) 🟡
🔹 EPS: $22.05 - $23.55 (Est. $22.86) 🟡
🔹 Non-GAAP EPS: $22.50 - $24.00
🔹 Gross Margin - OPEX / Revenue: 40.5% - 42.5% (Reported), 41.5% - 43.5% (Non-GAAP)
🔹 Effective Tax Rate: ~16%
🔹 Other Income (Expense): ($700M) - ($600M)
Key Product Q4 Performance:
🔹 Zepbound: $1.91B
🔹 Mounjaro: $3.53B; UP +60% YoY
🔹 Verzenio: $1.56B; UP +36% YoY
🔹 Jardiance: $1.20B; UP +50% YoY
🔹 Trulicity: $1.25B; DOWN -25% YoY
🔹 Taltz: $952M; UP +21% YoY
🔹 Humalog: $619.9M; UP +69% YoY
Operational Metrics:
🔹 COGS: $2.40B (Est. $2.51B) 🟢
🔹 Gross Profit: $11.13B (Est. $11.13B) 🟡
🔹 R&D Expenses: $3.02B (Est. $2.99B) 🟡; UP +18% YoY
🔹 SG&A Expenses: $2.42B (Est. $2.41B) 🟡; UP +26% YoY
🔹 Operating Expenses (R&D + SG&A): $5.44B (Est. $5.41B) 🟡
Strategic & Business Developments:
🔸 FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
🔸 FDA approved Omvoh for moderately to severely active Crohn's disease.
🔸 Positive SURMOUNT-5 trial results: Zepbound showed 47% greater weight loss vs. Wegovy.
🔸 Announced pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.
🔸 $3B investment to expand Kenosha County, Wisconsin manufacturing facility.
🔸 $15B share repurchase program announced alongside a 15% increase in quarterly dividend.
CEO David A. Ricks Commentary:
🔸 "2024 was a highly successful year for Lilly with major data readouts, expanding manufacturing, and launching key products. We enter 2025 with strong momentum, focusing on sustained financial performance and critical Phase 3 readouts."
In the following post, I would like to discuss the new US tariffs and their potential economic consequences. The background and the potential impact on inflation and companies, as well as the winners and losers on the stock market, will be discussed.
Again, of course, the stocks mentioned do not constitute investment advice, but merely serve as examples of possible beneficiaries or losers of tightening trade restrictions. Historical developments are no guarantee of future returns.
__________
In this post:
__________
The topic of "tariffs" is currently not only very present in the media, but the term "tariffs" has also been discussed with a strong increase in the past earnings calls of companies in the S&P 500, as the following chart shows [1].
The chart shows that the discussion about tariffs has intensified in recent months and is having an ever greater impact on the outlook in companies' annual reports.
The data is presented as a three-month average and broken down into various sectors, including e.g. industry, healthcare, consumer goods, information technology, etc.
I am curious to see how the stock markets will behave in the coming week. In addition to the current reporting season, the topic of "tariffs" will certainly dominate.
After the tough tariffs announced after Trump took office were not immediately enforced and there was a "slight" sigh of relief, there could now be a new reaction on the markets, as there was on Friday evening. slightly was already slightly noticeable on Friday evening when the markets turned towards the evening.
A looming trade conflict could not only affect individual companies, but also further fuel inflation in the US:
💰 Influence on inflation
On January 31, Deutsche Bank published a forecast on the potential impact of tariffs on the inflation rate [2]:
The chart compares the current forecast with the forecast before the "Trump" era and takes into account various scenarios for the passing on of tariffs (pass-through) by Canada and Mexico.
Two scenarios are considered: one with a 50% pass-through of tariffs (additional increase shown in dark green) and one with a 75% pass-through (light green). It is clear that the inflation rate could rise sharply again this year and fall again by 2027.
🛃 New tariffs in force & further measures planned
As of today, February 1, 2025, the US government and Donald Trump have imposed new import tariffs on Mexico, Canada and China:
According to the White House spokesperson, these measures are, among other things, a response to the failure of these countries to stop the influx of fentanyl and illegal immigrants into the USA. [3]
But this is just the beginning:
From mid-February, the USA will also impose tariffs on strategic goods [4], including:
🚨 Trump relies on escalation - Canada announces retaliation
Yesterday, Canadian government representatives, including Foreign Minister Mélanie Joly, tried to prevent the tariffs in Washington, but to no avail.
Trump made it clear before his departure to Mar-a-Lago [5]:
"We have a 200 billion dollar trade deficit with Canada. Why should we subsidize Canada?"
The EU could also soon be targeted, as Trump hinted:
"Absolutely! The European Union has treated us so terribly!"
🔄 Canada's reaction:
Prime Minister Justin Trudeau announced that Canada will not back down and will respond with "swift and robust countermeasures".
The government is planning a three-stage retaliation strategy [5]:
However, this last step in particular would be a double-edged sword, as Canada is heavily dependent on energy cooperation with the USA.
Economic experts in the US are already warning of the consequences of a trade war [5]:
But Trump remains firm:
"Maybe there will be short-term disruption, but in the long run the tariffs will make us very rich and very strong."
🌎 Possible consequences for the global economy
(a) Rising prices in the USA
(b) Retaliation & new trade wars?
(c) Effects on the stock market
🏆 Winners & losers - which companies will benefit, which will suffer?
Possible beneficiaries of the tariffs
US manufacturers of steel, aluminum & copper
Domestic pharmaceutical and biotech companies
Energy companies with US production
Chip manufacturers with US production
😥 Companies that could suffer from the tariffs
Chip manufacturers with global supply chains
Car manufacturers with global suppliers
Companies with strong export business
US retailers with a high import share
🧠 Possible investment strategies
Favor defensive sectors:
Exploit long-term opportunities in "reshoring":
Conclusion: Will the trade conflict escalate further?
With the new tariffs, Trump is taking a confrontational stance and Canada, Mexico and China are preparing for retaliatory measures. If further tariffs on European goods follow, the situation could worsen.
❓Which stocks do you think could be most affected? Which beneficiaries do you see?
Thanks for reading! 🤝
__________
Sources:
[4]
[5] https://www.tagesschau.de/ausland/amerika/usa-trump-strafzoelle-100.html
Principales creadores de la semana